Year None202120202019201820172016 Date Latest Press Release May 19, 2020 Eiger BioPharmaceuticals Announces FDA Acceptance of NDA for Filing with Priority Review of Zokinvy™ (lonafarnib) for Treatment of Progeria and Progeroid Laminopathies May 7, 2020 Eiger BioPharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update April 30, 2020 Eiger BioPharmaceuticals Announces First COVID-19 Patients Dosed with Peginterferon Lambda April 27, 2020 Eiger BioPharmaceuticals Announces EMA Validation of Lonafarnib MAA for Treatment of Progeria and Progeroid Laminopathies April 1, 2020 Eiger BioPharmaceuticals Provides Update on Clinical Development Activities and Business Operations During COVID-19 Pandemic March 23, 2020 Eiger BioPharmaceuticals Completes Submission of New Drug Application to FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies March 13, 2020 Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update January 7, 2020 Eiger BioPharmaceuticals Appoints Industry Veteran Eldon Mayer as Executive Vice President and Chief Commercial Officer January 6, 2020 Eiger Updates on 2019 Progress and 2020 Milestones Expected December 16, 2019 Eiger Initiates Rolling Submission of New Drug Application (NDA) with FDA for Lonafarnib for Treatment of Progeria and Progeroid Laminopathies Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »
